

About the Authors



Colin Stewart, MD

Dr. Colin Stewart is a Hematologist at the Cross Cancer Institute in Edmonton, Canada. He earned his medical degree from the University of Alberta, followed by residency training in Internal Medicine and Hematology at the University of Calgary and a clinical fellowship in Hematology Oncology at the University of Alberta. Dr. Stewart specializes in the treatment of lymphoma and myeloma. His research interests include lymphoma, the re-appraisal of autologous stem cell transplantation, and health economics.

Affiliations: Cross Cancer Institute & University of Alberta, Edmonton, Canada



Robert Puckrin, MD

Dr. Robert Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Comprehensive Cancer Centre, Alberta Blood and Marrow Transplant Program, and the University of Calgary in Calgary, Canada. Having obtained his medical degree from McGill University, he completed Internal Medicine training at the University of Toronto and subsequent training in Hematology and Hematopoietic Cell Transplantation and Cellular Therapy at the University of Calgary. His main clinical and research interests are in lymphoma, cellular therapy, clinical trials, and real-world data.

Affiliations: Arthur Child Comprehensive Cancer Centre & University of Calgary, Calgary, Canada.

Current Management of Relapsed or Refractory Classic Hodgkin Lymphoma in Canada

Colin Stewart, MD
Robert Puckrin, MD

Introduction

Classic Hodgkin lymphoma (HL) is a rare B-cell malignancy with approximately 1,150 new cases diagnosed annually in Canada.¹ Outcomes have improved substantially over the past several decades, with HL-related mortality declining by 2.2–3.0% annually since 1984, reflecting advances in both first-line and salvage therapies.¹ Despite this progress, 10–30% of patients develop primary refractory or relapsed (R/R) disease, with risk influenced by stage, treatment regimen, and clinical features.^{2–4} Relapse rates are further decreasing with contemporary first-line regimens such as nivolumab, doxorubicin, vinblastine, and dacarbazine (nivolumab-AVD) and brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), and are now estimated at 5–10% in advanced-stage disease.^{5,6} Key adverse prognostic factors at relapse include primary refractory disease, relapse within 12 months, and advanced-stage disease.^{7–9}

The introduction of novel targeted therapies, including the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) and the programmed death-1 (PD-1) inhibitors nivolumab and pembrolizumab, has led to improved outcomes in R/R HL.⁸ However, in Canada, access to targeted therapies has been constrained by delays in funding and restrictive approval criteria.^{10,11} In this review, we address common challenges and outline our approach to the treatment of adults with R/R HL within the contemporary Canadian context.

Second-Line Treatment in Patients Eligible for ASCT

Role of ASCT

In medically fit patients, the management of R/R HL has traditionally consisted of second-line platinum-based chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT). This approach is supported by two landmark randomized trials demonstrating significant improvements in event-free survival, though not overall survival, with ASCT compared to standard chemotherapy.^{12,13} Real-world data from the pre-novel agent era confirm durable remissions in approximately 50–60% of patients with R/R HL undergoing ASCT.^{9,14,15} ASCT remains an effective curative modality for fit older patients, as well as for those with primary refractory disease and early or late relapses.^{16–18}

Selection of Salvage Regimen

Choice of second-line regimen depends on patient fitness, institutional practice, and funding availability. Retrospective Canadian data support the use of gemcitabine, dexamethasone, and cisplatin (GDP), which has achieved overall response rates (ORR) of 62–71%, computed tomography (CT)-based complete response (CR) rates of 7–9%, transplantation rates of 88–96%, and 1.5-to-2-year progression-free survival (PFS) rates of 58–76%.^{19,20} The more intensive dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) regimen, primarily used in Alberta, demonstrated an ORR of 86%, CT-based




Figure 1. Treatment algorithm for relapsed or refractory Hodgkin lymphoma in Canada; courtesy of Colin Stewart, MD and Robert Puckrin, MD.

Abbreviations: ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; ASCT: autologous stem cell transplantation; BV: brentuximab vedotin; BV-AVD: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine; BrECADD: brentuximab, vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone; CMR: complete metabolic response; DICEP: dose-intensive cyclophosphamide, etoposide, cisplatin; escBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone; GDP: gemcitabine, dexamethasone, and cisplatin; HSCT: hematopoietic stem cell transplantation; HL: Hodgkin lymphoma; ICE: ifosfamide, carboplatin, etoposide; Nivo-AVD: nivolumab plus doxorubicin, vinblastine, and dacarbazine; PD: progressive disease; PD1: programmed death-1; PMR: partial metabolic response; R/R: refractory or relapsed

CR rate of 18%, transplantation rate of 95%, and 5-year PFS of 61%.¹⁵ Other established regimens include ifosfamide, carboplatin, etoposide (ICE), dexamethasone, cisplatin, cytarabine (DHAP), etoposide, high-dose cytarabine, cisplatin (ESHAP), and gemcitabine, vinorelbine, doxorubicin (GVD).²¹⁻²³

Pre-Transplant Response Assessment

Historically, patients with R/R HL could proceed to ASCT regardless of their response to salvage chemotherapy, and durable remissions were observed even among a subset with chemorefractory disease,^{15,24} although accurate response assessment was limited by CT-based imaging. In the positron emission tomography (PET) era, achieving a complete metabolic

response (CMR) prior to ASCT has emerged as a key prognostic factor, with PET-negative patients demonstrating 15–45% higher PFS compared to those with residual PET positivity.^{8,25,26} Notably, several studies have reported comparable PFS among patients attaining pre-transplant PET negativity after one versus two lines of salvage therapy, suggesting a potential role for additional salvage treatment to convert a partial metabolic response (PMR) to a CMR before ASCT.^{27,28} However, this approach has not been compared in prospective randomized trials against proceeding directly to ASCT in patients with PMR, and it remains unclear whether PET conversion itself causally improves outcomes or simply reflects more favourable disease biology. As such, it remains reasonable to proceed to

ASCT if an adequate PMR has been achieved particularly if alternative novel salvage regimens are unavailable, as over 50% of patients with a positive pre-transplant PET may still achieve durable remission.^{8,26}

Impact of Targeted Therapies Before ASCT

The introduction of BV and PD-1 inhibitors has led to multiple single-arm phase II studies evaluating novel second-line regimens before ASCT. BV-based sequential or concurrent chemotherapy combinations (e.g., BV with bendamustine, gemcitabine, ICE, DHAP, or ESHAP) have demonstrated promising outcomes, with ORRs of 68–100%, CMR rates of 62–81% transplantation rates of 73–96%, and 2-to-3 year PFS rates of 63–82%.^{28–32} Importantly, a randomized phase II trial demonstrated that the addition of BV to ESHAP increased CMR rates from 48% to 70%.³³

PD-1-based strategies have shown particularly promising activity in the pre-ASCT setting, with retrospective data demonstrating superior 2-year PFS among patients undergoing ASCT after PD-1 inhibitor therapy (88%) compared to BV (70%) or chemotherapy (67%).²⁶ Phase II studies of PD-1 inhibitors ± BV or chemotherapy (e.g., GVD, ICE, gemcitabine and oxaliplatin [GemOx]) have reported ORRs of 85–100%, CMR rates of 67–97%, transplantation rates of 79–95%, and 2-to-3 year PFS rates of 72–96% among all patients and >90% among those undergoing ASCT.^{34–39} Intriguingly, favourable 18-month PFS rates of 81% have been observed even among heavily pretreated, chemorefractory patients undergoing ASCT after third- or later-line PD-1 blockade, suggesting a paradoxical synergy between immune checkpoint inhibition and ASCT through deepened responses and/or resensitization to chemotherapy.⁴⁰

Despite these encouraging data, second-line BV and PD-1 inhibitors are not currently funded in Canada for patients eligible for ASCT. Additionally, the future role of BV or PD-1-based salvage regimens is unclear given the increasing incorporation of these agents into the first-line setting.^{5,6} Patients who are refractory to a targeted agent-containing regimen may be switched to an alternative novel agent and/or chemotherapy at relapse, whereas those with late relapse may be candidates for retreatment. Indeed, Canada's Drug Agency has endorsed retreatment with BV and PD-1 inhibitors for selected patients who relapse >6–12 months after treatment,^{11,41} and

small datasets support this approach in R/R HL.^{42–44} The phase II CCTG HD11 trial, which randomized patients to BV plus pembrolizumab versus GDP prior to ASCT, has completed accrual and is expected to inform optimal salvage strategies in the Canadian context, including for patients with prior exposure to BV and PD-1 inhibitors.

Can ASCT be Omitted?

The efficacy of PD-1-based regimens has prompted interest in the potential for omitting ASCT in the era of novel agents. In a provocative phase II study, 24 patients who achieved CMR with pembrolizumab plus GVD received pembrolizumab maintenance without ASCT, resulting in a 2-year PFS of 60%. Outcomes were inferior in patients with stage IV disease, with a 2-year PFS of 37% versus 72% in those with stage I–III disease, although most patients who relapsed were successfully rescued with ASCT.⁴⁵ Another prospective trial reported a 2-year PFS rate of 79% among 73 patients with CMR after ESHAP ± BV who received maintenance BV instead of ASCT.³³ In addition, several pediatric studies also reported favourable outcomes with consolidative radiotherapy in lieu of ASCT in selected patients with low-risk relapse.^{46–48} Although promising, these findings are preliminary in nature and insufficient to alter standard practice, particularly given the established curative potential of ASCT and its manageable safety profile in a generally fit population. However, ongoing randomized studies are evaluating whether ASCT can be safely omitted or deferred in selected patients.

Maintenance Therapy After ASCT

Post-transplant maintenance with 16 cycles (48 weeks) of BV is funded in Canada based on the AETHERA trial, which demonstrated a significant improvement in 5-year PFS (59% vs 41%) among high-risk patients who received ASCT for R/R HL, including those with primary refractory disease, early relapse within 12 months, or extranodal involvement.^{7,49} However, BV maintenance has not been shown to improve overall survival, may represent overtreatment for some patients already cured by ASCT, and is associated with risks of neuropathy (67%), neutropenia (35%), gastrointestinal toxicity (>20%), and premature treatment discontinuation due to intolerance (33%). Its use should therefore be individualized, with the greatest benefit observed in patients with a positive pre-transplant PET or ≥2 enrolment risk factors.

Real-world data suggest the PFS benefit of maintenance BV is maintained despite dose reductions or early discontinuation.⁵⁰ Importantly, the AETHERA trial was conducted before the routine incorporation of targeted agents into first and second-line therapy. While there is conflicting retrospective data regarding the utility of maintenance BV among patients previously exposed to targeted agents,^{51,52} there is no evidence to support its use among those refractory to BV. Maintenance BV does not appear to be necessary for those undergoing ASCT after PD-1-containing regimens, given the high cure rates with this strategy.⁵²

Patients Ineligible for ASCT

Transplant ineligibility may result from advanced age, comorbidities, poor performance status, chemorefractory disease, or inadequate stem cell mobilization. Prior to the availability of BV and PD-1 inhibitors, outcomes for this population with conventional chemotherapy were poor.⁵³ In the randomized KEYNOTE-204 trial, which enrolled 304 adults with R/R HL who were either ineligible for (63%), or who had relapsed after (37%) ASCT, pembrolizumab was associated with a higher ORR (66% vs 54%) and a significantly improved PFS compared with BV (median 13 vs 8 months).⁵⁴ Pembrolizumab now represents the preferred funded second-line option for transplant-ineligible patients without prior PD-1 inhibitor resistance. BV is generally reserved for patients who are intolerant of or refractory to PD-1 inhibitors; however, in most Canadian provinces, its funding is restricted to the post-ASCT setting.

Of note, response assessment during PD-1 therapy may be challenging due to false-positive PET findings and pseudoprogression related to immune cell infiltration.⁵⁵ In cases of equivocal response, treatment continuation with repeat imaging and/or biopsy is appropriate to clarify disease status.⁵⁵ Data also support continuation of PD-1 blockade beyond progression in selected patients with asymptomatic, indolent relapse to maximize the clinical benefit of this therapy.^{56,57}

Multiply Relapsed Disease

Post-ASCT Relapse

Outcomes for patients relapsing after ASCT have improved in the current era of PD-1 inhibitors and BV, with 4-year overall survival

rising from 43% to 71%.⁸ Both agents are broadly funded in Canada for patients relapsing after ASCT, and the superiority of PD-1 inhibitors over BV was confirmed in post-ASCT relapses in the KEYNOTE-204 trial.⁵⁴ While the median PFS with these agents is in the range of 9–15 months, long-term follow-up demonstrates 5-year PFS rates of 14–22%, suggesting a curative potential in a subset of patients.^{58–60} Among patients who relapse while off treatment, rechallenge with PD-1 inhibitors or BV is associated with an ORR of >50–60% and a median PFS of 6–13 months.⁴⁴

Double-Refractory Disease

Ultimately, a subset of patients develop resistance to both BV and PD-1 inhibitors (“double-refractory disease”), representing an area of high unmet need with limited evidence to guide therapy. Radiotherapy can be an effective option for localized relapses, although most patients will eventually relapse outside the irradiated field.⁶¹ Emerging data suggest that epigenetic therapies may restore sensitivity to PD-1 inhibitors.⁶² Other palliative-intent strategies include chemotherapy (e.g., bendamustine, vinblastine, gemcitabine) or everolimus, though responses are typically partial and short-lived.^{63–65} Whenever possible, enrolment in clinical trials should be sought, as there are encouraging results from early-phase studies of CD30-directed CAR T-cell therapy, allogeneic natural killer cells, bispecific antibodies, and novel antibody-drug conjugates and immune checkpoint inhibitors.^{66–69}

Contemporary Outcomes of Allogeneic HSCT

Allogeneic hematopoietic stem cell transplantation (HSCT) remains an underappreciated but important curative option for patients with multiply relapsed disease who have exhausted other options. Several contemporary studies have reported remarkably high PFS rates of 69–84% following allogeneic HSCT after PD-1 therapy in heavily pretreated patients, suggesting a PD-1-mediated enhancement of the graft-versus-lymphoma effect.^{70,71} The safety profile of allogeneic HSCT has improved with the adoption of reduced-intensity conditioning and post-transplant cyclophosphamide.^{70,72,73} However, because pre-transplant exposure to PD-1 therapy has been associated with increased risks of acute graft-versus-host disease, a washout period of 4–12 weeks is recommended prior to

transplantation owing to the long half-lives of these agents.^{72,74}

Given the prognostic importance of achieving adequate disease control prior to allogeneic HSCT,^{70,72} the timing of transplantation should be individualized, taking into account the disease course, patient preferences, and anticipated availability of bridging therapies. Referral for allogeneic HSCT is recommended by the time of initiation of a second targeted therapy in multiply relapsed patients. Patients with high-risk features, such as refractory disease or short remission durations, may benefit from consolidation with allogeneic HSCT while responding to a second targeted agent, whereas others may defer transplantation until progression on both agents, followed by re-induction with chemotherapy prior to transplant. Donor lymphocyte infusion may be considered in the setting of post-transplant relapse, with reported ORR of 56–79%.^{75,76}

Conclusions

Outcomes in R/R HL have become increasingly favourable due to the integration of targeted therapies across multiple lines of treatment. However, this progress has introduced new uncertainties, including the impact of novel first-line regimens on salvage strategies, the evolving role of ASCT, and the optimal management of patients with double-refractory disease.

In Canada, the most immediate challenge remains access. Despite robust evidence, targeted therapies are inconsistently funded, particularly in the pre-transplant and transplant-ineligible settings, creating a gap between evidence and practice. Addressing these disparities will be essential to ensure that advances in therapy translate into meaningful improvements in patient outcomes.

Correspondence

Robert Puckrin, MD

Email: Robert.Puckrin@albertahealthservices.ca

Financial Disclosures

C.S.: Honoraria: Sanofi, GSK, Roche, and AstraZeneca.

R.P.: Honoraria: Abbvie, AstraZeneca, Beigene, Eli Lilly, Incyte, Kite, Janssen, Merck, Pfizer, Roche, and Seagen

References

1. Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2025. Toronto, ON: Canadian Cancer Society; 2025 [accessed 2026 Apr 6]. Available from: cancer.ca/Canadian-Cancer-Statistics-2025-EN
2. Rodday AM, Evens AM, Maurer MJ, Upshaw JN, Counsell N, Rossetti S, et al. An individualized prediction model for early-stage classic Hodgkin's lymphoma. *NEJM Evid.* 2025;4(9):EVIDoa2500115. doi:10.1056/EVIDoa2500115
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J Med.* 1998;339(21):1506–1514. doi:10.1056/NEJM199811193392104
4. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. *J Clin Oncol.* 2012;30(27):3383–3388. doi:10.1200/JCO.2011.41.0910
5. Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. *Lancet.* 2024;404(10450):341–352. doi:10.1016/S0140-6736(24)01315-1
6. Herrera AF, LeBlanc M, Friedberg JW. Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma. Reply. *N Engl J Med.* 2025;392(1):102. doi:10.1056/NEJMc2414269
7. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2015;385(9980):1853–1862. doi:10.1016/S0140-6736(15)60165-9
8. Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, et al. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. *Blood.* 2023;141(22):2727–2737. doi:10.1182/blood.2022018827
9. Bröckelmann PJ, Müller H, Gillesen S, Yang X, Koeppel L, Pilz V, et al. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. *Leukemia.* 2022;36(3):772–780. doi:10.1038/s41375-021-01442-8
10. Davies GA, Orav JE, Brantley KD. Survival Outcomes for US and Canadian patients diagnosed with Hodgkin lymphoma before and after brentuximab vedotin approval for relapsed/refractory disease: a retrospective cohort study. *Curr Oncol.* 2024;31(7):3885–3894. doi:10.3390/curroncol31070287
11. Canada's Drug Agency. CADTH reimbursement recommendation pembrolizumab (Keytruda). Canadian Journal of Health Technologies. 2021;1(11):1–16. Available from: <https://www.cda-amc.ca/sites/default/files/DRR/2021/PC0236%20Keytruda%20-%20CADTH%20Final%20Rec%20Final.pdf>

12. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet*. 1993;341(8852):1051–1054. doi:10.1016/0140-6736(93)92411-I
13. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet*. 2002;359(9323):2065–2071. doi:10.1016/S0140-6736(02)08938-9
14. Sureda A, Genadieva Stavrik S, Boumendil A, Finel H, Khvedelidze I, Dietrich S, et al. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. *Bone Marrow Transplant*. 2020;55(11):2170–2179. doi:10.1038/s41409-020-0929-y
15. Shafey M, Duan Q, Russell J, Duggan P, Balogh A, Stewart DA. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. *Leuk Lymphoma*. 2012;53(4):596–602. doi:10.3109/10428194.2011.624227
16. Desai SH, Spinner MA, Sykora A, Bachanova V, Evens AM, Goyal G, Kahl BS, Dorritie K, Azzi J, Kenkre VP, Chang C. Outcomes of autologous stem cell transplant in older adults with relapsed/refractory classic Hodgkin lymphoma. *Blood*. 2024;144 (Supplement 1):570. <https://doi.org/10.1182/blood-2024-199845>
17. Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, et al. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. *Blood Adv*. 2024;8(21):5458–5466. doi:10.1182/bloodadvances.2024013743
18. Bröckelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J, et al. Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin Study Group HD7 to HD12 Trials. *J Clin Oncol*. 2017;35(13):1444–1450. doi:10.1200/JCO.2016.71.3289
19. Moccia AA, Hitz F, Hoskins P, Klasa R, Power MM, Savage KJ, et al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. *Leuk Lymphoma*. 2017;58(2):324–332. doi:10.1080/10428194.2016.1193852
20. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. *Cancer*. 2006;106(2):353–360. doi:10.1002/cncr.21587
21. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. *Blood*. 2001;97(3):616–623. doi:10.1182/blood.v97.3.616
22. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. *Ann Oncol*. 2002;13(10):1628–1635. doi:10.1093/annonc/mdf221
23. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. *Ann Oncol*. 2007;18(6):1071–1079. doi:10.1093/annonc/mdm090
24. Gerrie AS, Power MM, Shepherd JD, Savage KJ, Sehn LH, Connors JM. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. *Ann Oncol*. 2014;25(11):2218–2223. doi:10.1093/annonc/mdu387
25. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. *Blood*. 2010;116(23):4934–4937. doi:10.1182/blood-2010-05-282756
26. Desai SH, Moskowitz AJ, Merryman RW, Shah H, Pederson LD, Geyer SM, et al. PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma. *Blood*. 2026;147(10):1125–1134. doi:10.1182/blood.2025030151
27. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. *Blood*. 2012;119(7):1665–1670. doi:10.1182/blood-2011-10-388058
28. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. *Lancet Oncol*. 2015;16(3):284–292. doi:10.1016/S1470-2045(15)70013-6
29. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. *Blood*. 2018;132(1):40–48. doi:10.1182/blood-2017-11-815183
30. Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase ii trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant*. 2015;21(12):2136–2140. doi:10.1016/j.bbmt.2015.07.018
31. Stamatoullas A, Ghesquières H, Feugier P, André M, Le Bras F, Gac AC, et al. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. *Leuk Lymphoma*. 2022;63(13):3063–3071. doi:10.1080/10428194.2022.2107204

32. Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. *Haematologica*. 2021;106(4):1129–1137. doi:10.3324/haematol.2019.243238
33. Balari AM, Cespedes JN, Castera MJ, Hernandez FM, Domenech ED, De la Cruz Vicente F, et al. The addition of brentuximab vedotin to ESHAP significantly increases the rate of metabolic complete remissions vs chemotherapy alone. in patients with relapsed/refractory classical Hodgkin's lymphoma. Final results of a phase IIB prospective randomized clinical trial (BRESELIBET). *Blood*. 2024;144 (Supplement 1):3049. <https://doi.org/10.1182/blood-2024-211527>
34. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. *J Clin Oncol*. 2021;39(28):3109–3117. doi:10.1200/JCO.21.01056
35. Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, et al. Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial. *JAMA Oncol*. 2023;9(5):683–691. doi:10.1001/jamaoncol.2022.7975
36. Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. *Blood*. 2022;139(25):3605–3616. doi:10.1182/blood.2022015423
37. Mei M, Palmer J, Lee HJ, Isufi I, Chen R, Tsai NC, et al. Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma. *Hemasphere*. 2025;9(5):e70126. doi:10.1002/hem3.70126
38. Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. *Blood*. 2021;138(6):427–438. doi:10.1182/blood.2020009178
39. Ding K, Liu H, Ma J, Yang H, Cao L, Wang H, et al. Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. *Haematologica*. 2023;108(8):2146–2154. doi:10.3324/haematol.2022.282266
40. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. *Blood Adv*. 2021;5(6):1648–1659. doi:10.1182/bloodadvances.2020003556
41. Canada's Drug Agency. CADTH reimbursement recommendation brentuximab vedotin (Adcetris). *Canadian Journal of Health Technologies*. 2024;4(9):1–24. Available from: <https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0371REC-Adcetris.pdf>
42. Nishimura Y, Han Y, Toumeh N, Janda G, Fujiwara Y, Durani U, et al. Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma. *Blood Neoplasia*. 2025;2(3):100134. doi:10.1016/j.bneo.2025.100134
43. Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: a report from the EBMT Lymphoma Working Party. *Cancer*. 2019;125(1):90–98. doi:10.1002/cncr.31755
44. Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, et al. Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. *Blood Cancer J*. 2025;15(1):45. doi:10.1038/s41408-025-01257-1
45. Moskowitz A, Shah GL, Ganesan N, Chang T, Drill E, Davey T, Hancock H, Munayirji B, Douglas M, Santarosa AM, Casper E. Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin.
46. Hoppe BS, Milgrom SA, Renfro LA, Wu Y, Schwartz CL, Constine LS, et al. Transplant-free salvage therapy for low-risk relapsed pediatric Hodgkin lymphoma: a nonrandomized clinical trial. *JAMA Oncol*. 2025;11(3):340–342. doi:10.1001/jamaoncol.2024.5648
47. Daw S, Claviez A, Kurch L, Stoevesandt D, Attarbaschi A, Balwierz W, et al. Transplant and nontransplant salvage therapy in pediatric relapsed or refractory Hodgkin lymphoma: The EuroNet-PHL-R1 phase 3 nonrandomized clinical trial. *JAMA Oncol*. 2025;11(3):258–267. doi:10.1001/jamaoncol.2024.5636
48. Daw S, Cole PD, Hoppe BS, Hodgson D, Beishuizen A, Garnier N, et al. Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults: a nonrandomized clinical trial. *JAMA Oncol*. 2025;11(3):249–257. doi:10.1001/jamaoncol.2024.5627

49. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood*. 2018;132(25):2639–2642. doi:10.1182/blood-2018-07-861641
50. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, et al. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. *Haematologica*. 2023;108(11):3025–3032. doi:10.3324/haematol.2023.282780
51. Martínez C, Khvedelidze I, Fekom M, Deau Fischer B, Marouf A, Ghesquières H, et al. Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group. *Bone Marrow Transplant*. 2025;60(6):879–887. doi:10.1038/s41409-025-02568-4
52. Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah HR, Geyer S, et al. Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma. *Blood Adv*. Published online March 27, 2026. doi:10.1182/bloodadvances.2025018683
53. Böll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, et al. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. *J Clin Oncol*. 2013;31(35):4431–4437. doi:10.1200/JCO.2013.49.8246
54. Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. *Lancet Oncol*. 2021;22(4):512–524. doi:10.1016/S1470-2045(21)00005-X
55. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. *Blood*. 2016;128(21):2489–2496. doi:10.1182/blood-2016-05-718528
56. Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, et al. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. *Oncologist*. 2020;25(6):e993–e997. doi:10.1634/theoncologist.2020-0040
57. Cohen JB, Engert A, Ansell SM, Younes A, Trneny M, Savage KJ, Ramchandren R, Collins G, Fanale MA, Armand P, Zinzani PL. Nivolumab treatment beyond investigator-assessed progression: outcomes in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 Checkmate 205 study. *Blood*. 2017;130 (Supplement 1):650. https://doi.org/10.1182/blood.V130.Suppl_1.650.650
58. Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. *Blood*. 2023;142(10):878–886. doi:10.1182/blood.2022019386
59. Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. *Blood Adv*. 2023;7(20):6266–6274. *Blood Adv*. 2024;8(4):829–831. doi:10.1182/bloodadvances.2023012353. Erratum for: *Blood Adv*. 2023 Oct 24;7(20):6266–6274. doi:10.1182/bloodadvances.2023010334
60. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. *Blood*. 2016;128(12):1562–1566. doi:10.1182/blood-2016-02-699850
61. Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. *J Clin Oncol*. 2005;23(7):1522–1529. doi:10.1200/JCO.2005.05.022
62. Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, et al. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. *Blood*. 2023;142(16):1359–1370. doi:10.1182/blood.2023020485
63. Moskowitz AJ, Hamlin PA, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. *J Clin Oncol*. 2013;31(4):456–460. doi:10.1200/JCO.2012.45.3308
64. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. *Am J Hematol*. 2010;85(5):320–324. doi:10.1002/ajh.21664
65. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood*. 2011;118(19):5119–5125. doi:10.1182/blood-2011-07-362475
66. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. *J Clin Oncol*. 2020;38(32):3794–3804. doi:10.1200/JCO.20.01342
67. Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. *Nat Med*. 2025;31(6):1987–1993. doi:10.1038/s41591-025-03640-8

68. Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, et al. Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study. *Blood Adv*. 2025;9(23):6205–6217. doi:10.1182/bloodadvances.2024015600
69. Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, et al. Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: an open-label phase 1/2 study [Abstract]. *J Clin Oncol*. 2022;40(16 suppl). doi:10.1200/JCO.2022.40.16_suppl.7545
70. Perales MA, Awan FT, Boumendil A, Patel J, Castagna L, Angelucci E, et al. Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis. *Blood*. 2025;146(8):1011–1029. doi:10.1182/blood.2024027197
71. Tabbara N, Zahurak M, Sterling CH, Trutzer IM, Jedrych J, Swinnen LJ, et al. Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma. *Blood Adv*. 2025;9(5):1202–1209. doi:10.1182/bloodadvances.2024015048
72. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. *Leukemia*. 2021;35(9):2672–2683. doi:10.1038/s41375-021-01193-6
73. Montoro J, Ngoya M, Kulagin A, Giebel S, Broers AEC, Bramanti S, et al. PTCy vs CNL-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT. *Blood Adv*. 2024;8(15):3985–3992. doi:10.1182/bloodadvances.2024013328
74. Ahmed S, Kumar A, Carpenter P, Herrera A, Kelly K, Pinnix C, et al. American Society of Transplantation and Cellular Therapy Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma. *Transplant Cell Ther*. 2026;32(3):250–260. doi:10.1016/j.jtct.2025.12.944
75. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. *J Clin Oncol*. 2011;29(8):971–978. doi:10.1200/JCO.2010.32.1711
76. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. *Lancet*. 2005;365(9475):1934–1941. doi:10.1016/S0140-6736(05)66659-7